Share Price:

APNASPENAspen Pharmacare Hldgs13615265 (1.99%)

Aspen is in a closed period from 1st January 2026 until the publication of the interim results on the JSE SENS platform on the 3rd March 2026.

Aspen Invests R2.7 Billion in Expanding Global Business

Johannesburg – JSE listed Aspen Pharmacare Holdings Limited (Apn) has announced an investment by its offshore subsidiary, Aspen Global Incorporated, of GBP 170 million (approximately R2.7 billion) for the acquisition of four pharmaceutical products from GlaxoSmithKline (GSK). Aspen Global has acquired the intellectual property rights to the branded pharmaceuticals Eltroxin, Imuran, Lanoxin and Zyloric for… Continue reading Aspen Invests R2.7 Billion in Expanding Global Business

Aspen wins significant portion of ARV tender

In addition to maintaining the supply contract for existing tender items, Aspen has also secured volumes for two new products, Aspen Efavirenz and Tenofivir. Tenofivir is a key new molecule to the ARV tender. Increased usage is anticipated over the tender period. Aspen secured more than 50% by volume of the entire ARV tender based… Continue reading Aspen wins significant portion of ARV tender

Shelys Africa Limited

Aspen Pharmacare Holdings Limited is pleased to announce the conclusion of a deal for the acquisition of 60% of the share capital of Shelys Africa Limited, with operations in East and Central Africa with effect from 01 May 2008. Shelys Africa Limited is the holding company of a group of East African pharmaceutical companies (“the… Continue reading Shelys Africa Limited

Motivation, direction and structure!

After my interview with him it once again dawned on me how important it is to enjoy what you do; to have a passion for it; to be motivated! In fact, when I carefully reflect on all the interviews with great leaders the recipe for success becomes clearer and clearer: You have to have motivation,… Continue reading Motivation, direction and structure!

Aspen records 15% year-on-year revenue increase

Johannesburg – JSE listed Aspen (Apn), Africa’s largest pharmaceutical manufacturer, has recorded consistently positive results for the period ended December 2007. Revenue increased by 15 percent to R2.2 billion (R1.9 billion). Operating profit increased by 24 percent to R634 million (R 512 million). Earnings per share increased by 31 percent to 125.0 cents (95.3 cents).… Continue reading Aspen records 15% year-on-year revenue increase

Aspen and Strides Enter Into Broad and Strategic Partnership

Johannesburg South Africa, and Bangalore, India: Aspen Pharmacare (Aspen), Africa’s largest pharmaceutical manufacturer and the largest generics manufacturer in the southern hemisphere, has entered into a series of transactions with Bangalore-based Strides Arcolab Limited (Strides), one of India’s largest exporters of pharmaceutical products. The transactions comprise: the acquisition by Aspen of 50% of Strides’ Latin… Continue reading Aspen and Strides Enter Into Broad and Strategic Partnership

Aspen operating profit exceeds R1bn

Johannesburg – JSE listed Aspen (Apn), Africa’s largest pharmaceutical manufacturer, has announced a sound set of results for the financial year ended June 30, 2007. These results take into account the higher effective tax rate of 28,9% (2006:25.3 percent). Revenue increased by 17% to R4,026 billion (R3.449 billion). Operating profit increased by 20% to R1,077… Continue reading Aspen operating profit exceeds R1bn

Aspen Scientific and Technical capabilities provide strong export growth potential

JSE listed Aspen (APN), Africa and the Southern hemisphere’s largest pharmaceutical manufacturer, has hosted the Honourable Minister Mosibudi Mangena, MP, South African Minister of Science and Technology, at their flagship Port-Elizabeth manufacturing site. The visit was aimed at exploring areas where the Department of Science and Technology (DST) can support local manufacturers in realising greater… Continue reading Aspen Scientific and Technical capabilities provide strong export growth potential

Closed Period

Aspen is in a closed period from 1st January 2026 until the publication of the interim results on the JSE SENS platform on the 3rd March 2026.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.

Corporate

Our career opportunities are across the corporate spectrum, including Human Capital, Digital Technology, Legal, and Risk & Sustainability. Our employees are given the opportunity to hone their skills and develop the experience of excellence in their chosen field in the pharmaceutical industry.

View our teams below: